Fate Therapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 6.83, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Fate Therapeutics Inc in Mar 31 2026 quarter, has decreased to 53 days, compared to 74 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 526 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 2117 to 3651.

What is Receivable Turnover Ratio?
What is Fate Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

FATE Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	-70.74 %	-74.12 %	-83.47 %	33.11 %	180.42 %
Y / Y Revenue Change	-20.26 %	-26.4 %	-43.36 %	-71.84 %	-15.38 %
Receivable Turnover Ratio (TTM)	6.83	4.92	3.56	2.95	4.8
FATE's Total Ranking	# 3651	# 2117	# 2294	# 3119	# 2836
Accounts Receivable average collection period days	53	74	103	124	76
Seq. Receivable Change	-23.14 %	34.31 %	-51.11 %	-42.02 %	-32.01 %
Seq. Revenue Change	-5.11 %	-21.37 %	-8.7 %	17.07 %	-12.42 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 64
Healthcare Sector	# 527
Overall Market	# 3651

Receivable Turnover Ratio Statistics
High	Average	Low
0.19	0.06	0.01
(Mar 31 2023)		(Mar 31 2024)

FATE Company Profile • Back to FATE Efficiency Comparisons • Compare FATE Receivables Turnover Ratio to its Competitors

Financial Statements
Fate Therapeutics Inc 's Accounts Receivable	$ 1 Millions	Visit FATE's Balance sheet
Fate Therapeutics Inc 's Sales TTM	$ 6 Millions	Visit FATE's Income Statement
Sources of FATE's Revenues		Visit FATE's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
FATE's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
FATE's Growth Rates	FATE's Roa	FATE's Inventory Turnover Ratio	FATE's Dividend Comparisons
FATE's Profitability Ratios	FATE's Roi	FATE's Asset Turnover Ratio	FATE's Dividend Growth
FATE's Valuation Ratios	FATE's Roe	FATE's Financial Strength Ratios	FATE's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Jaguar Health Inc	24.65	$ 29.569 Millions	$ 1.200 Millions
Kiniksa Pharmaceuticals International Plc	24.63	$ 754.045 Millions	$ 30.618 Millions
Polomar Health Services, Inc.	24.47	$ 1.649 Millions	$ 0.067 Millions
Agenus Inc	24.33	$ 123.866 Millions	$ 5.091 Millions
Igc Pharma Inc	23.44	$ 1.166 Millions	$ 0.050 Millions
Cytomx Therapeutics Inc	23.09	$ 35.542 Millions	$ 1.539 Millions
Siga Technologies Inc	22.41	$ 93.777 Millions	$ 4.186 Millions
Lipocine Inc	22.09	$ 2.002 Millions	$ 0.091 Millions
Fonar Corporation	21.15	$ 105.338 Millions	$ 4.981 Millions
Neuraxis Inc	20.94	$ 4.282 Millions	$ 0.204 Millions
Vystar Corporation	20.58	$ 0.048 Millions	$ 0.002 Millions
Lifemd Inc	19.91	$ 177.869 Millions	$ 8.934 Millions
Longeveron Inc	19.07	$ 1.216 Millions	$ 0.064 Millions
Sonida Senior Living Inc	18.82	$ 411.850 Millions	$ 21.878 Millions
Nutriband Inc	16.79	$ 1.803 Millions	$ 0.107 Millions
Bioadaptives Inc	16.64	$ 0.024 Millions	$ 0.001 Millions
Premier Air Charter Holdings Inc	16.33	$ 33.205 Millions	$ 2.033 Millions
Bioage Labs Inc	15.90	$ 10.316 Millions	$ 0.649 Millions
Escalon Medical Corp	15.15	$ 11.445 Millions	$ 0.756 Millions
Nurix Therapeutics Inc	15.11	$ 71.779 Millions	$ 4.750 Millions
Rosecliff Acquisition Corp I	15.05	$ 23.433 Millions	$ 1.557 Millions
Lexicon Pharmaceuticals Inc	14.91	$ 69.643 Millions	$ 4.670 Millions
Qhslab Inc	14.80	$ 2.775 Millions	$ 0.188 Millions
Nexgel Inc	14.19	$ 10.382 Millions	$ 0.732 Millions
Sutro Biopharma Inc	14.04	$ 99.608 Millions	$ 7.095 Millions
Precipio inc	13.93	$ 25.831 Millions	$ 1.854 Millions
China Pharma Holdings Inc	13.86	$ 3.992 Millions	$ 0.288 Millions
Talkspace Inc	13.67	$ 239.269 Millions	$ 17.501 Millions
Marpai Inc	13.59	$ 17.125 Millions	$ 1.261 Millions
Amneal Pharmaceuticals Inc	13.56	$ 3,045.530 Millions	$ 224.634 Millions

Date modified: 2026-08-30T14:48:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.